VXRT - Vaxart stock trades higher after Jefferies initiated with a buy citing vaccine platform

Alexey Koza/iStock via Getty Images Jefferies has begun the coverage of Vaxart ([[VXRT]] +5.8%) with a buy recommendation noting that its vaccine platform allows the development of oral vaccines for prophylaxis from infectious diseases. The price target at $13.00 per share implies a premium of ~65.6% to the last close. Comparing the superior efficacy of Vaxart’s oral flu vaccine to Sanofi’s injection, Fluzone based on a proof-of-concept study, the platform has been de-risked the analysts argue. Despite the generation of various immune cells in Phase 1 studies, Vaxart’s oral COVID-19 vaccine candidate failed to generate serum IgG antibodies, the firm notes. However, the company’s intention to start a dose confirmation study in H2 2021 will help determine the go-forward strategy. Meanwhile, subject to CDC recommendation for vulnerable populations, Vaxart’s norovirus vaccine could help the company to generate over $1B annually, the analysts wrote. In May, Vaxart outlined plans to start

For further details see:

Vaxart stock trades higher after Jefferies initiated with a buy citing vaccine platform